The dual GIP/GLP-1 receptor agonist tirzepatide improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes

被引：0
|
作者：
Wilson, J. M. [1 ]
Nikooienejad, A. [1 ]
Bowsman, L. M. [1 ]
Schroeder, J. M. [1 ]
Hamlin, D. M. [1 ]
Robins, D. A. [1 ]
Riesmeyer, J. S. [1 ]
Haupt, A. [1 ]
Duffin, K. L. [1 ]
Ruotolo, G. [1 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
来源：
DIABETOLOGIA | 2019年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1161
引用
收藏
页码：S558 / S559
页数：2
相关论文
共 50 条
  • [21] Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis
    Karagiannis, Thomas
    Avgerinos, Ioannis
    Liakos, Aris
    Del Prato, Stefano
    Matthews, David R.
    Tsapas, Apostolos
    Bekiari, Eleni
    DIABETOLOGIA, 2022, 65 (08) : 1251 - 1261
  • [22] The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes
    Wilson, Jonathan M.
    Nikooienejad, Amir
    Robins, Deborah A.
    Roell, William C.
    Riesmeyer, Jeffrey S.
    Haupt, Axel
    Duffin, Kevin L.
    Taskinen, Marja-Riitta
    Ruotolo, Giacomo
    DIABETES OBESITY & METABOLISM, 2020, 22 (12): : 2451 - 2459
  • [23] Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis
    Thomas Karagiannis
    Ioannis Avgerinos
    Aris Liakos
    Stefano Del Prato
    David R. Matthews
    Apostolos Tsapas
    Eleni Bekiari
    Diabetologia, 2022, 65 : 1251 - 1261
  • [24] Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide
    Urva, Shweta
    Quinlan, Tonya
    Landry, John
    Martin, Jennifer
    Loghin, Corina
    CLINICAL PHARMACOKINETICS, 2021, 60 (08) : 1049 - 1059
  • [25] Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide
    Urva, Shweta
    Quinlan, Tonya
    Landry, John
    Ma, Xiaosu
    Martin, Jennifer A.
    Benson, Charles T.
    CLINICAL PHARMACOKINETICS, 2022, 61 (07) : 1057 - 1067
  • [26] Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide
    Shweta Urva
    Tonya Quinlan
    John Landry
    Jennifer Martin
    Corina Loghin
    Clinical Pharmacokinetics, 2021, 60 : 1049 - 1059
  • [27] Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide
    Shweta Urva
    Tonya Quinlan
    John Landry
    Xiaosu Ma
    Jennifer A. Martin
    Charles T. Benson
    Clinical Pharmacokinetics, 2022, 61 : 1057 - 1067
  • [28] Tirzepatide - a dual GIP/GLP-1 receptor agonist - a new antidiabetic drug with potential metabolic activity in the treatment of type 2 diabetes
    Nowak, Mariusz
    Nowak, Wojciech
    Grzeszczak, Wladyslaw
    ENDOKRYNOLOGIA POLSKA, 2022, 73 (04) : 745 - 755
  • [29] GIP and GLP-1 receptor agonism in the therapy of type 2 diabetes with a focus on tirzepatide
    Nauck, Michael A.
    Blueher, Matthias
    Meyhoefer, Sebastian M.
    Heitmann, Elke
    Goergens, Sven W.
    DIABETOLOGIE UND STOFFWECHSEL, 2023, 18 (06) : 475 - 487
  • [30] Tirzepatide, a dual GIP/GLP-1 receptor agonist, is effective and safe when added to basal insulin for treatment of type 2 diabetes (SURPASS-5)
    Dahl, D.
    Onishi, Y.
    Norwood, P.
    Huh, R.
    Patel, H.
    Rodriguez, A.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 13 - 14
12345